Tests drug combinations to prevent graft-versus-host disease after stem cell transplant
Compares drug combinations to prevent graft-versus-host disease in adults with blood cancers.
Key facts
- Who runs it
- Center for International Blood and Marrow Transplant Research
- Where
- Birmingham, Boston, Chapel Hill, Charlottesville, Detroit, Duarte, Houston, Miami, New York, Palo Alto, Portland, Seattle, and Westwood, United StatesSee the 13 sites
- Trial code
- Registry title
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 358 people, planned
- Started
- 25 Jul 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional, 3 groups
- Treatments tested
- Conditioning Regimen A
- Conditioning Regimen B
- Conditioning Regimen C
- Conditioning Regimen D
- Conditioning Regimen E
- Hematopoietic Cell Transplantation
- PTCy (50 mg/kg D3, D4)
- PTCy (25 mg/kg D3, D4)
- Post-transplant Tacrolimus
- Post-transplant Mycophenolate mofetil
- Post-transplant Abatacept
- Post-transplant Ruxolitinib
- Supportive Care: Growth Factors
- Supportive Care: Blood Products
- Supportive Care: Infection Prophylaxis
- Supportive Care: Intravenous immune globulin (IVIG)
- Supportive Care: Seizure prophylaxis
- Supportive Care: Monitoring and management of CRS
- Supportive Care: Prophylaxis against infections
- Supportive Care: Lipid elevations
- Study treatment compliance
- Prohibited Concomitant Therapy
- Permitted Concomitant Therapy
- Record updated
- 17 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with blood cancers who will have a stem cell transplant from an unrelated donor whose tissue type is only partly the same. It compares drug combinations that prevent graft-versus-host disease.
- Age
- Adults 18 years or older; for full-strength conditioning, under 66 years (chemotherapy-based) or under 61 years (TBI-based).
- Sex
- All sexes can join.
- Disease stage
- Leukemia (acute leukemia, CML, CLL), MDS, MPN, CMML or lymphoma, with no sign of active disease or with chemosensitive disease. Acute leukemia must be in remission with 5% or fewer marrow blasts. MDS must have under 10% marrow blasts.
- Earlier treatment
- A prior donor stem cell transplant or an own-cell transplant in the past 3 months excludes. No other GVHD prevention trial at the same time.
- Biomarker or test result
- The donor must have a partial tissue type (HLA) similarity of 4/8 to 7/8 at HLA-A, -B, -C and -DRB1, and be aged 16-35. HIV-positive people can join only if viral load is undetectable on treatment.
Main reasons for not taking part
- A fully HLA-matched related donor or 8/8 matched unrelated donor is available
- Earlier stem cell transplant from a donor, or own-cell transplant within the past 3 months
- Pregnant or breastfeeding
- Uncontrolled bacterial, viral or fungal infection at the time of transplant preparation
- HIV with a persistently positive viral load
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Age 18 to < 66 years (chemotherapy-based conditioning) or < 61 years (TBI-based conditioning) at the time of signing informed consent
- Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Planned MAC regimen (see Table 8 in Section 7.4 for allowed MAC regimens)
- Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35
- Product planned for infusion is MMUD T-cell replete PBSC as allograft
- HCT-CI < 5 (Appendix H - Hematopoietic Cell Transplant Comorbidity Index Scoring). The presence of prior malignancy will not be used to calculate HCT-CI for this trial, to allow for the inclusion of patients with secondary or therapy-related AML or MDS
- One of the following diagnoses:; AML, ALL, or other acute leukemia in first remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning; Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% vs 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning
- Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results
- Estimated creatinine clearance ≥ 45mL/min calculated by equation
- Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥ 50% and forced expiratory volume in first second (FEV1) predicted ≥ 50% based on most recent PFT results
- Liver function acceptable per local institutional guidelines
- KPS of ≥ 70% (Appendix I - Performance Status)
- Age ≥ 18 years at the time of signing informed consent
- Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Planned NMA/RIC regimen (see
- Table 9 in Section 7.4 for allowed NMA/RIC regimens)
- Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 16-35
- Product planned for infusion is MMUD T-cell replete PBSC allograft
- One of the following diagnoses:; Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with < 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning; Patients with MDS with no circulating blasts and with < 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with < 5% vs 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning; Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation; Higher-risk chronic myelomonocytic leukemia (CMML) according to CMML-specific prognostic scoring system or high-risk MDS/myeloproliferative neoplasms (MPN) not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment; Patients with lymphoma with chemosensitive disease at the time of transplantation; Patients with primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera or MDS with grade 4 fibrosis
- Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure
- Estimated creatinine clearance ≥ 45mL/min calculated by equation
- Pulmonary function: DLCO corrected for hemoglobin ≥ 50% and FEV1 predicted ≥ 50% based on most recent PFT results
- Liver function acceptable per local institutional guidelines
- KPS of ≥ 60% (Appendix I - Performance Status)
Who cannot take part
- Subjects with a prior allogeneic transplant
- Subjects with an autologous transplant within the past 3 months
- Concurrent enrollment on a GVHD prevention clinical trial
- Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant
- Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen
- Patients who are HIV-positive with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well-controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled
- Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available
- Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
- Subjects who are breastfeeding or pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 66 years old?
Where in United States
- University of Alabama BirminghamBirmingham, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- University of North CarolinaChapel Hill, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- University of VirginiaCharlottesville, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- Karmanos Cancer InstituteDetroit, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- City of HopeDuarte, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- MD AndersonHouston, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- University of MiamiMiami, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- Memorial Sloan KetteringNew York, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- StanfordPalo Alto, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Leigh Anne Blackmon, MSWTaking people
- University of Kansas Medical CenterWestwood, United StatesContact: Leigh Anne Blackmon, MSWTaking people
About the trial
What the trial wants to find out
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination.
Read full original descriptionShow less
Participants will:
* Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
The 3 groups in the trial
- Control/SOCTreatment being tested
Shared comparator control group
Treatment: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Study treatment compliance, Prohibited Concomitant Therapy, and Permitted Concomitant Therapy
- ACCEL-001Treatment being tested
Intervention 1
Treatment: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Abatacept, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Study treatment compliance, Prohibited Concomitant Therapy, and Permitted Concomitant Therapy
- ACCEL-002Treatment being tested
Intervention 2
Treatment: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, and Prohibited Concomitant Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Plain-language title
- Tests drug combinations to prevent graft-versus-host disease after stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06859424, who can take part
- Record updated
- 17 March 2026